No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study.
Guida M, Bartolomeo N, Quaglino P, Madonna G, Pigozzo J, Di Giacomo AM, Minisini AM, Tucci M, Spagnolo F, Occelli M, Ridolfi L, Queirolo P, De Risi I, Quaresmini D, Gambale E, Chiaron Sileni V, Ascierto PA, Stigliano L, Strippoli S, On Behalf Of The Italian Melanoma Intergroup Imi Study.
Guida M, et al. Among authors: quaresmini d.
Cancers (Basel). 2021 Jan 26;13(3):475. doi: 10.3390/cancers13030475.
Cancers (Basel). 2021.
PMID: 33530579
Free PMC article.